case_images: PMC10487696_01
case_images: Clinical course of this patient before and after administration of gefapixant, a P2X3 antagonist.
case_images: IMCRJ-16-497-g0001.jpg
case_images: PMC10487696_01_IMCRJ-16-497-g0001.jpg
case_images: f0001
case_images: After 6 months of follow-up, her cough relapsed, but additional treatment with a Th2 inhibitor, suplatast tosilate, was only partially effective since the VAS improved from 70 mm to 60 mm (Figure 1), which may be related to inability to evade antigen and the existence of multiple causes of cough. Other additional treatments with budesonide/formoterol, tiotropium, rabeprazole, dextromethorphan, clarithromycin, amitriptyline, itraconazole, and bakumondo-to were ineffective (Figure 1). August 5, 2022, and confirmed improvement from 4.3 to 8.0 (Figure 1). As of April 24, 2023, after 38 weeks of follow-up, her cough had remained stable, with a VAS score of 10 mm and an LCQ score of 14.7, as shown in Figure 1.